Prospect Park Capital Announces Appointment of New Director

TORONTO, ONTARIO--(Marketwired - April 20, 2016) - Prospect Park Capital Corp. ("Prospect Park") (TSX VENTURE:PPK), a public healthcare focused investment corporation, is pleased to announce that its board of directors has appointed Seymour H. Fein, M.D. as a director to replace Frank Mancuso who is focusing on other ventures.

Dr. Fein is a graduate of the University of Pennsylvania with a B.A. in biology. He received his M.D. degree from New York Medical College. Dr. Fein's professional activities have been focused on drug development research for over 35 years. He has been extensively involved in the successful development of numerous drugs, biologics and medical devices over this time leading to FDA approvals for over 20 drugs (NDAs, sNDAs, BLAs) and devices (PMAs). Dr. Fein began his pharmaceutical career at Hoffman-LaRoche as senior research physician. He then joined Bayer Pharmaceuticals as medical director responsible for multiple therapeutic areas. Dr. Fein served as Director of Clinical R&D at Anaquest/Ohmeda for almost five years. Since 1994 Dr. Fein has operated pharmaceutical consulting companies including Fein & Associates and CNF Pharma which provide clinical, regulatory and analytical consulting services to the industry. Dr. Fein is also a founder and medical director of ChiRhoClin Inc., a privately owned pharmaceutical company focused on developing orphan drug products. He is a principal and co-founder of Serenity Pharmaceuticals which has developed a new drug for nocturia. Dr. Fein has served as a member of the Board of Directors of development stage biotechnology and pharmaceutical companies.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.